Staphylococcus aureus-aka staph-is among the most extensively studied human pathogens. Unfortunately, that knowledge hasn't made staph infections any easier to treat, particularly in the lungs.
Staph bacteria are notoriously adept at evading the host's immune response and shrugging off even the most powerful antibiotics, often leading to pneumonia.
"We know how staph attack lung cells and what makes these bacteria especially virulent. But most drugs or vaccines aimed at these mechanisms haven't worked," says Alice Prince, a physician and scientist who studies staph and other airway pathogens at Columbia University Vagelos College of Physicians and Surgeons.
New research from Prince may have finally unearthed this pathogen's Achilles' heel: its choice of food.
Losing the taste for sugar
Staph's food of choice is sugar, in the form of glucose. However, this energy source is not readily available in the lung, especially after immune cells rush in to fight the infection and gobble up most of the supply.
![Andreacarola Urso, PhD](https://www.cuimc.columbia.edu/sites/default/files/styles/cola_media_1280/public/media/general/2024-09/urso_andreacarola_princelab.jpeg?itok=1W80MrT7)
Andreacarola Urso, PhD, a 2023 graduate of the Molecular Pharmacology and Therapeutics Program, led the study. Photo courtesy of Alice Prince / Columbia University Irving Medical Center.
In response, staph begin to dine on the amino acid proline, which is abundant in infected lungs. Until now, it wasn't known how staph accomplish this nifty culinary switch.
To learn more, Prince and her team analyzed the genetic and metabolic changes in staph isolated from cystic fibrosis patients at various stages of infection. (People with cystic fibrosis are especially vulnerable to staph, so lung cultures are regularly taken, providing researchers with a wealth of study material.)
Led by Andreacarola Urso, PhD, a recent graduate of the molecular pharmacology and therapeutics program, researchers found that when staph sense glucose is running low, they trigger a mechanism called carbon catabolite repression (CCR), which limits organisms to consuming one type of carbon at a time, such as glucose.
"But CCR can also reprogram bacteria to consume another energy source, if necessary," says Prince. "In this case, CCR directs staph to exploit the availability of proline."
Starving staph
Once staph make the switch to proline, their food supply is effectively endless. The infection stimulates the lung into making collagen to repair lung tissue damaged by the bacteria. A key component of collagen is proline.
"The lung increases proline synthesis and provides the food that S. aureus need to proliferate and coat the airways," Prince says.
A drug that stops collagen production can slow bacterial growth in mice infected with staph, the researchers found, but that approach is not practical for people. "You need collagen to repair your airways," says Prince.
Instead, Prince thinks that interfering with CCR to prevent staph's consumption of proline may prevent chronic infections, though no such drugs currently exist. "Interfering with CCR won't stop the initial stage of staph infection, but it could stop these organisms from forming persistent colonies where they can hide from antibiotics and our immune system," she says.
The same strategy also may apply to other bacteria that employ CCR, including Pseudomonas aeruginosa, another common source of antibiotic-resistant lung infections.
References
More information
Alice Prince, MD, is the John M. and Yvonne T. Driscoll Professor of Pediatrics in the Division of Infectious Diseases at Columbia University Vagelos College of Physicians and Surgeons.
All study authors (from Columbia unless noted): Andreacarola Urso, Ian R. Monk (University of Melbourne), Ying-Tsun Cheng, Camilla Predella, Tania Wong Fok Lung, Erin M. Theiller (Children's Hospital of Philadelphia), Jack Boylan, Sofya Perelman, Swikrity U. Baskota, Ahmed M. Moustafa (Children's Hospital of Philadelphia), Gaurav Lohia, Ian A. Lewis (University of Calgary), Benjamin P. Howden (University of Melbourne), Timothy P. Stinear (University of Melbourne), Nicolino V. Dorrello, and Victor Torres.
This work was supported by grants from the National Institutes of Health (1R35HL135800) and the National Science Foundation.
The authors declare no competing interests.